MMV390048 40 mg
MMV_MMV390048_16_01
Phase 1 small_molecule completed
Quick answer
MMV390048 40 mg for Malaria is a Phase 1 program (small_molecule) at CNS Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CNS Pharmaceuticals
- Indication
- Malaria
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed